138 related articles for article (PubMed ID: 11394370)
1. The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease.
Pioruńska-Stolzmann M; Pioruńska-Mikołajczak A
Pharmacol Res; 2001 Apr; 43(4):359-62. PubMed ID: 11394370
[TBL] [Abstract][Full Text] [Related]
2. Effect of simvastatin on trioleylglycerol hydrolysis and transacylation with cholesterol in serum of outpatients with coronary heart disease.
Pioruńska-Stolzmann M; Pioruńska-Mikolajczak A; Mikolajczyk Z
Drugs Exp Clin Res; 2003; 29(1):37-43. PubMed ID: 12866362
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E1 influences serum cholesterol esterase and lipase activity in different ways.
Pioruńska-Stolzmann M
Int J Tissue React; 1999; 21(3):79-83. PubMed ID: 10645515
[TBL] [Abstract][Full Text] [Related]
4. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease.
Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY
Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259
[TBL] [Abstract][Full Text] [Related]
5. [Changes of elastic properties of magistral arteries in patients with ischemic heart disease during treatment with atorvastatin and simvastatin].
Iliukhin OV; Kalganova EL; Babkin AA; Lopatin IuM
Kardiologiia; 2005; 45(12):31-4. PubMed ID: 16353044
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
7. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
8. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
9. [Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia].
Tvorogova MG; Susekov AV; Semenova OA; Kukharchuk VV; Titov VN
Ter Arkh; 1998; 70(12):8-13. PubMed ID: 10067240
[TBL] [Abstract][Full Text] [Related]
10. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT).
Mabuchi H; Kita T; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2002 Dec; 66(12):1096-100. PubMed ID: 12499612
[TBL] [Abstract][Full Text] [Related]
11. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
Ito MK; Stolley SN; Morreale AP; Lin JC; Marcus DB
Am J Health Syst Pharm; 1999 Jun; 56(11):1107-13. PubMed ID: 10385458
[TBL] [Abstract][Full Text] [Related]
12. [The effects after withdrawal of simvastatin on brachial artery endothelial function in patient with coronary heart disease or risk factors].
Chen H; Ren JY; Wu B; Liu X; Wang RJ; Li LJ; Luo Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jun; 35(6):531-5. PubMed ID: 17711713
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering for prevention of coronary heart disease: what policy now?
Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
[TBL] [Abstract][Full Text] [Related]
14. Statins in the prevention of coronary heart disease.
Williamson DR; Pharand C
Pharmacotherapy; 1998; 18(2):242-54. PubMed ID: 9545143
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
16. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.
Tomás M; Sentí M; García-Faria F; Vila J; Torrents A; Covas M; Marrugat J
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2113-9. PubMed ID: 10978257
[TBL] [Abstract][Full Text] [Related]
17. [LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
März W
MMW Fortschr Med; 2003 Dec; 145(50):46-9. PubMed ID: 14963971
[TBL] [Abstract][Full Text] [Related]
18. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia.
Matsuzaki M; Kita T; Mabuchi H; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2002 Dec; 66(12):1087-95. PubMed ID: 12499611
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers.
Ritzel U; Leonhardt U; Näther M; Schäfer G; Armstrong VW; Ramadori G
J Hepatol; 2002 Apr; 36(4):454-8. PubMed ID: 11943414
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
